🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 17, 2026

Across 50 SEC filings dated April 17, 2026, primarily from financials, energy/infra, and select consumer discretionary names, Q1 2026 bank earnings dominate with average YoY net income growth of ~17% (e.g., FNB +18%, First Financial +16.6%, Truist +19%) but QoQ declines averaging 20-80% due to merger charges and NIM compression (-3 to -5 bps across Regions, Truist, FNB). M&A activity surges with accretive deals like Uinta's $20M refinery acquisition (EBITDA 3x growth via Shell offtake), Fifth Third's $12.7B Comerica integration (NII +34% YoY), and TransDigm's Stellant buy ($1B financing). IPO/SPAC momentum evident in QuasarEdge's $115M upsized offering and Liftoff Mobile's 21% YoY customer growth S-1. Proxy season launches with 20+ annual meetings May-June, mostly neutral/positive (Energy Fuels, Firefly highlight growth). Consumer discretionary outliers like Atour Lifestyle show 35% YoY revenue surge (retail/manachised hotels), while risks emerge in debt defaults (Borealis $16M acceleration) and exec churn (American Axle). Portfolio implication: Favor resilient banks with buybacks (Truist $1.1B), monitor NIM trends; alpha in infra M&A and IPOs amid mixed sector sentiment (28% positive, 24% mixed, 44% neutral).

25 high priority 25 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 17, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (with broader financial context from first 28 new filings), healthcare activity remains sparse, focusing on biotech governance (Tyra Biosciences, Dare Bioscience, Emmaus Life Sciences director changes) and funding (Revolution Medicines $500M convertible notes, CEL-SCI S-1 offering), signaling pipeline investment amid neutral sentiment. Abbott Laboratories resolved infant formula litigation overhang via preliminary settlement approval. Dominating filings are regional banks' Q1 2026 earnings (FFIN +16.6% YoY NI, Regions +15% adj EPS YoY, Truist +25% EPS YoY, Ally +90% adj EPS YoY, Chemung +53.3% YoY NI), averaging 37% YoY net income/EPS growth but with QoQ NII declines (-0.8% to -2.8%) and NIM compression (-3 to -5 bps in 3/5) due to deposit shifts. Capital allocation leans shareholder-friendly (Truist $1.1B buyback, News Corp $1B program, Chemung $0.34 dividend), with proxy season ramping (10+ AGMs May-June). No insider trading patterns detected; sentiment mixed (positive in appointments/debt, neutral in proxies/13Fs). Portfolio implication: Opportunistic healthcare catalysts amid resilient bank earnings, watch NIM trends and biotech AGMs for conviction signals.

17 high priority 33 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 17, 2026

Across 50 DEF 14A filings dated April 17, 2026, for US companies' 2026 annual meetings (mostly virtual, May-June), overarching themes include frequent leadership transitions (e.g., Energy Fuels, Etsy, Cars.com, Portillo's) signaling strategic refreshes, robust governance practices (independent boards, say-on-pay votes with high prior support like Casella's 96%), and equity incentive plan expansions (e.g., Varonis, Cytokinetics, indie Semiconductor) amid biotech/tech growth. Period-over-period trends show strong revenue/EBITDA growth in outliers like Casella Waste (+18% YoY revenue, +17.3% EBITDA), Waystar Health (double-digit YoY quarterly revenue to >$1B), Yelp ($1.46B record revenue, +19% EPS), and Otis (5% service sales growth), but mixed results with net income declines (Casella -41.9% YoY, Otis GAAP EPS -14%) due to depreciation/acquisitions. Positive sentiment dominates energy/clean tech (Energy Fuels, Firefly Aerospace) and services, neutral elsewhere; capital allocation favors buybacks (Etsy -14M shares) and returns (Otis $1.5B). Market implications: High say-on-pay alignment supports stability, but dilution risks from equity plans and reverse splits (Banzai, Nauticus) warrant caution; portfolio-level outperformance in waste/health vs. benchmarks like Russell 2000.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 17, 2026

A surge of 16 S-1 and S-4 filings on April 17, 2026, signals an active IPO pipeline dominated by biotechs (Odyssey, Evommune, CEL-SCI), AI/tech (Cerebras, Liftoff, SmartKem, Algorhythm), medical services (GMR, Mobia, CapsoVision), and niche plays like energy (Fervo) and SPACs (Amanat), with several resale registrations highlighting dilution pressures. Period-over-period trends reveal biotech challenges: Odyssey's collaboration revenue plunged 33% YoY to $3.0M while R&D expenses rose 12% to $126.6M and G&A up 38% to $37.5M, widening net losses 15% to $148.6M; Liftoff bucks the trend with 21% YoY Demand Side Customer growth to 881 and 29% YoY SDK app integrations to 163,708. Mixed sentiment prevails (7/16 filings), with neutral in IPO pure-plays and negative in high-dilution resales; no insider trading activity disclosed across filings, but capital allocation leans toward reinvestment (no dividends in Evommune, Mobia, CEL-SCI). Forward-looking catalysts include IPO proceeds for clinical trials (Odyssey OD-001 UC trials, SmartKem milestones) and controlled company structures post-IPO (Liftoff Blackstone, Fervo CEO/CTO super-votes, GMR KKR). Portfolio-level implications: monitor biotech burn rates amid cash buffers ($216.6M Odyssey), resale dilution risks, and tech growth outliers for relative outperformance.

16 high priority 16 total filings
· daily

Global High-Priority Regulatory Events — April 17, 2026

Across 50 filings on April 17, 2026, dominant themes include widespread corporate distress in Indian finance, telecom, and manufacturing sectors with 7+ insolvencies/CIRP/defaults (e.g., Vivimed Labs, MTNL ₹9,262 Cr default), contrasting positive SPAC activity and M&A (Viking, QuasarEdge $100M IPO, Tri Pointe merger). US retail faces acute pressure via QVC's Chapter 11 bankruptcy risking equity cancellation, while Chinese ADRs show polarized results: revenue growth in lifestyle/tech (Atour +35% YoY, Niu +31% YoY, Tencent Music +15.9% YoY) offset by declines in social/gaming (Zhihu -24% YoY, DouYu -10.6% YoY). Period trends reveal margin volatility (e.g., FFIN NIM stable at 3.86% despite expense +9.2% YoY) and NAV drops (EQUUS -45% YoY), with no broad insider selling/buying patterns but positive C-suite appointments signaling conviction. Capital allocation leans conservative amid distress (few dividends/buybacks), favoring debt restructurings (Emergent Bio +flexibility). Implications: Short Indian distressed names, long SPAC de-SPAC catalysts, monitor QVC restructuring vote; portfolio tilt to resilient Chinese growth vs. avoid overleveraged US retail.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 17, 2026

Across 11 filings, financial results reveal stark divergence: robust growth in tech/media (Netflix +16% revenue, FDCTech +30%) contrasts with declines in consumer, real estate, and SPACs (Hooker -12%, Sunrise -15%, Farmhouse -85%). Period-over-period trends show 5/11 companies with revenue growth averaging +25% YoY (Netflix, FDCTech, MiniMed, Dream Homes, Autoliv), but 6/11 reported widening losses or net asset declines (e.g., EQUUS NAV -45%, Sunrise impairment $21.8M). Margin resilience in select names (FDCTech gross +1010bps to 54.8%, Hooker +180bps) offsets compressions elsewhere (MiniMed gross -8%). Capital allocation mixed with Netflix buybacks at $1.27B (down YoY) and Dream Homes distributions $1.97M eroding equity -41%. SPACs like Tech&Telecom and Renewable show deepening deficits amid zero revenue. Implications: Bullish for high-growth outliers like Netflix; caution on cyclical/declining sectors with portfolio-level loss trends signaling selective rotation opportunities.

11 high priority 11 total filings
· daily

US SEC Trading Suspension Halt Orders — April 17, 2026

All five companies in this USA Trading Suspensions stream faced Nasdaq deficiency notices between April 15-17, 2026, signaling acute listing compliance risks with uniformly negative sentiment (100% negative across filings) and high materiality (9/10 average). Three firms (MBIO, ALBT, VRME) violated Rule 5550(a)(2) due to common stock closing below $1.00 for 30 consecutive business days (March 1-April 14/17 periods), while two (GITS, NKLR) breached Rule 5250(c)(1) via untimely 10-K filings for FY ended Dec 31, 2025. No immediate trading halts occurred, with grace periods extending to June 15 (compliance plans) and October 12-14, 2026 (full compliance), but failure risks delisting, appeals, or reverse splits. Absent enriched period-over-period financial trends or insider activity, the cluster highlights microcap distress patterns, potentially signaling broader small-cap liquidity/operational challenges amid no reported YoY revenue/margin data. Portfolio implication: elevated volatility and downside bias near catalyst dates, with 60-180 day windows for remediation but low success odds without capital raises.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 17, 2026

Across 43 filings in the USA Corporate Distress & Bankruptcy stream (33 new), acute distress signals dominate with Chapter 11 prepacks by QVC Group ($2.9B credit + $2.15B notes accelerated, equity cancellation expected) and Cumulus Media ($600M debt elimination approved), plus Marizyme's Assignment for Benefit of Creditors (full asset transfer). Six small-caps (Global Interactive, Mustang Bio, Avalon GloboCare, VerifyMe, Terra Innovatum) face Nasdaq deficiencies for late 10-Ks or sub-$1 bids over 30 days, with 180-day compliance windows to Oct 2026. Counter-trends include debt refinancings (Emergent Bio: maturity to 2031, -200bps interest; AMC: 12.75% notes to 10.5% term loan +4yrs; InvenTrust: $250M notes at 5.44% avg) providing liquidity relief. No aggregate YoY/QoQ revenue/margin trends available, but restructuring themes signal leverage overload in media/retail/tech. Implications: Short equities in bankruptcies/delisting risks; favor post-reorg debt/equity in prepacks; monitor Oct catalysts for volatility.

43 high priority 43 total filings
· daily

US Executive Officer Management Changes SEC — April 17, 2026

Across 35 SEC filings on USA Executive & Director Changes dated April 17, 2026, leadership transitions dominate with 18 departures/retirements (e.g., CEOs at Reed's, Fermi, Southern Copper) and 22 appointments/promotions (e.g., new CEOs at Oportun, directors at Rockwell, Tyra), yielding neutral sentiment in 70% of cases amid stable comp structures. Positive developments include experienced hires like Doug Bland at Oportun (30+ years exp, PayPal credit lead) and equity retention tools (Lixte RSUs, Hooker PSUs targeting 10% EPS CAGR to 2029), signaling alignment; negatives feature sudden CEO losses (Southern Copper passing) and terminations (American Axle). No explicit YoY/QoQ revenue declines noted, but comp trends show base salary stability ($355k-$1M range) with equity ramps (e.g., Forward Industries 825k units to new CFO). Forward-looking catalysts cluster around FY2027 incentives (30% revenue/70% op income weights at Hooker) and CEO searches (Fermi update Apr20). Sector patterns: Biotechs/manufacturing exhibit 40% transition rate vs. overall 50%, with retention repricings (Pliant options to $1.33); implications for investors - favor internal successions (Carpenter CEO shift) over interims for reduced volatility.

35 high priority 35 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — April 17, 2026

Four companies announced insolvency proceedings on or around April 16-17, 2026, highlighting acute distress in consumer retail (QVC affiliates) and media/biotech sectors amid broader economic pressures. QVC Group and QVC Inc., affiliates, initiated prepackaged Chapter 11 filings in Texas with strong creditor support (>75% for RCF Claims, >55% for QVC Notes) but face $6.55B in accelerated debt ($2.9B credit, $2.15B notes, $1.5B debentures) and equity cancellation, signaling total shareholder wipeout. Cumulus Media secured court approval for its prepackaged plan to eliminate $600M debt pending FCC nod, offering relative outperformance via quicker deleveraging. Marizyme opted for Florida state-law Assignment for Benefit of Creditors, liquidating assets with no operational continuity implied. No period-over-period financial trends disclosed across filings, but inherent distress implies prior YoY revenue/margin declines leading to insolvency; portfolio-level pattern shows 3/4 pursuing prepackaged restructurings for ~90-day emergence, favoring creditors over equity. Market implications: heightened speculation risk, delistings, and short opportunities in consumer/media names.

4 high priority 4 total filings
· daily

US Merger & Acquisition SEC Filings — April 17, 2026

The 'USA M&A & Takeover Activity' stream reveals a surge in SPAC-related developments across 10 filings, with 7/10 involving blank check companies announcing IPOs, mergers, extensions, or structural changes, signaling robust M&A momentum in 2026. Key themes include successful SPAC IPOs (QuasarEdge raising $115M total), definitive business combinations (Viking-NorthStar at $300M pre-money, Sizzle-Trasteel), and deadline extensions (Israel Acquisitions to May 15, Bayview to May 19), indicating persistent deal-making despite some delays. FFIN's Q1 results show banking sector resilience with 16.6% YoY net income growth and 13.5% NII rise, but QoQ asset declines highlight deposit pressures. Positive sentiment dominates (5/10 filings), with mixed/neutral in earnings and stalled deals; no insider selling patterns noted, but capital deployments into trusts support ongoing pursuits. Forward-looking catalysts cluster in Q3 2026 (Viking close) and May 2026 extensions, positioning SPACs for de-SPAC upside. Portfolio-level trend: 6/10 filings report no declines, emphasizing growth via M&A over organic trends.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 17, 2026

Overnight SEC filings reveal mixed Q1 2026 bank earnings with YoY revenue and EPS growth averaging ~15-20% across Regions (+5% rev, +15% adj EPS), Truist (+5% rev TE, +25% EPS), Ally (+36% rev, +90% adj EPS), FNB (+9% rev), and State Street (+16% rev), but consistent QoQ NIM compression (e.g., Regions -3bps to 3.67%, Truist -5bps to 3.02%, FNB -3bps to 3.25%) signaling deposit competition pressures. Chinese ADRs show divergent trends: robust growth in Atour (+35% YoY rev to $1.4B), Niu (+31% rev), Tencent Music (+16% rev, +60% profit), ZTO (+11% rev) contrasted by declines in Zhihu (-24% rev), DouYu (-11% rev). SPAC activity surges with QuasarEdge $100M IPO priced at $10/unit and Viking/NorthStar $300M deal (Q3 close, $30M PIPE). M&A and financing positives include Tri Pointe merger consent at $47/share, Uinta $20M acquisition with Shell offtake tripling EBITDA, InvenTrust $250M notes. QVC bankruptcy filing (debts accelerated to $6.55B, equity cancellation) is a major retail distress signal. Capital allocation leans toward buybacks (News Corp $1B program, Autoliv $300-500M) and debt refinancings (Emergent $150M term loan at -200bps). Portfolio trend: Financials resilient YoY (avg ROTCE ~12-18%) amid margin squeezes; watch June proxy catalysts for governance shifts.

30 high priority 20 medium 50 total filings
· daily

Biotech Small-Cap Approvals — April 16, 2026

The April 16, 2026 period in biotech small-cap approvals featured 2 'other' approvals (0 NMEs, 0 biosimilars per mix, 0 label expansions), both neutral signals for identical APOTEX biosimilar approvals of ALPHA-TOCOPHEROL ACETATE on 2026-04-09. No dominant therapeutic area theme emerges, as indications and market details are NOT_DISCLOSED. The highest-conviction signal is APOTEX ALPHA-TOCOPHEROL ACETATE biosimilar (fallback) approval with neutral strength (5/10) and materiality (5/10), implying limited differentiated commercial upside. Key risk/watch item: complete lack of peak sales, exclusivity, pricing power, and market position data hinders investment assessment; monitor APOTEX launch execution and originator competitive dynamics.

2 total filings
· daily

New Drug Approvals (Original) — April 16, 2026

The FDA approval period of April 16, 2026 to April 16, 2026 featured 2 'Other' approvals (0 NMEs, 0 biosimilars, 0 label expansions), both neutral signals for identical ALPHA-TOCOPHEROL ACETATE approvals to APOTEX on April 9, 2026. No dominant therapeutic area theme is evident, as details remain limited with all commercial metrics NOT_DISCLOSED. The highest-conviction signal is the neutral fallback biosimilar-like approval for ALPHA-TOCOPHEROL ACETATE by APOTEX, implying modest market entry potential without disclosed exclusivity or peak sales. Key risk/watch item: lack of originator disclosure limits competitive erosion assessment; monitor APOTEX launch dynamics.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — April 16, 2026

Federal construction and infrastructure contracts obligated $149,336,416 during April 16-16, 2026, representing a 1/0 defense/civilian split with the Department of Defense as the sole agency. SKANSKA USA CIVIL NORTHEAST INC captured the entire amount via a $149.3M award, delivering a bullish signal (strength 7/10, materiality 8/10) in defense construction. This highest-conviction win underscores DOD infrastructure priorities amid NDAA-aligned spending. However, the December 5, 2023 award date flags CR vulnerability for initial funding stability. Watch for execution risks on this large obligation given unknown pricing structure and competition details.

1 total filings
· daily

DOD Defense Contracts Intelligence — April 16, 2026

A single $149,336,416 obligation was recorded from the Department of Defense to SKANSKA USA CIVIL NORTHEAST INC, comprising 100% defense spending with 1/1 defense-related contract and no civilian activity. This award, dated 2023-12-05, delivers a bullish signal (7/10 strength, 8/10 materiality) indicating DOD investment in civil construction. The dominant agency is the Department of Defense, with no clear sector theme due to limited details. Highest-conviction signal is the sizable $149.3M win for SKANSKA USA CIVIL NORTHEAST INC, potentially enhancing backlog in defense infrastructure. Key risk is Continuing Resolution (CR) vulnerability given the December award timing, warranting monitoring for funding stability.

1 total filings
· daily

Defense Manufacturing Contracts — April 16, 2026

NASA awarded Axiom Space Inc a $99,911,446 firm fixed price delivery order for Extravehicular Activity (EVA) Demonstration, representing 100% civilian obligations with 0/1 defense-related contracts in this period. This substantial commitment in guided missile and space vehicle manufacturing underscores NASA's ongoing investment in space vehicle equipment leasing through full and open competition. The highest-conviction bullish signal is Axiom Space's $99.9M obligation, with $77.4M already outlayed and potential upside to $171.6M base + options. A key watch item is progress toward full obligation fulfillment and exercise of $71.7M in unexercised options by the 2028-08-09 potential end date. High pricing risk on the firm fixed price structure warrants caution for performance execution.

1 total filings
· daily

DHS Homeland Security Contracts — April 16, 2026

DHS homeland security contracts totaled $93,853,558 in obligations over the period, comprising 0/1 defense-related awards and thus fully civilian-focused. The dominant theme is stable advisory and assistance services for DHS's CWMD Acquisition Division, with LMI Consulting, LLC securing the sole $93.8M materiality-weighted Delivery Order awarded in 2020. Highest-conviction signal is neutral (5/10 strength), reflecting strong execution with $101.5M outlayed exceeding the obligation on this Time and Materials vehicle, balanced against the contract's nearing end. Annualized revenue estimate of $16.8M underscores steady DHS civilian revenue for LMI through 2026. Key risk is re-compete exposure post-April 2026 end date under full and open competition. Watch outlay progress versus obligation and $27.6M subaward execution.

1 total filings
· daily

New Federal Contractors — April 16, 2026

These 12 new federal contracts aggregate $2,556,508,585 in total obligations, with 11 civilian awards ($2,407M) across State, HHS, USAID, NASA, DHS, USDA, DOE, and GSA, plus one $149M DOD construction award to Skanska USA Civil Northeast Inc. Dominant themes include Dept of State services ($1.07B via CGI Federal's $620M passport support and AAR's $449M aviation maintenance) and HHS preparedness ($434M via Agiliti Health's $327M ventilators/PAPR and DLH's $107M IT). Highest-conviction bullish signals stem from strong outlay execution on AAR ($290M outlaid), Agiliti ($272M outlaid), and ABT Global ($160M outlaid on $279M USAID malaria control). Key risk is near-term recompetes for maturing contracts like CGI Federal (ends 2024-05-09) and AAR (ends 2024-05-31) amid no indicated extensions.

12 total filings
· daily

Significant Contract Modifications ($10M+) — April 16, 2026

These 12 significant contract modifications totaling $2,556,508,585 in obligations are entirely civilian agency-focused (0/12 defense-related per aggregate, though Skanska USA Civil Northeast Inc. holds the sole $149M DOD award), spanning State, HHS, USAID, NASA, DHS, USDA, DOE, and GSA. Dominant themes include IT facilities management, medical equipment maintenance, aviation support, and facilities remediation, with bullish signals from strong outlay execution in high-value awards like AAR Government Services ($449M State) and Agiliti Health ($327M HHS). Highest-conviction bullish signal is Agiliti Health's $327M HHS ventilator maintenance contract with $272M already outlayed and extension potential to 2028. Key risk is high firm-fixed-price execution exposure across multiple contracts (e.g., Amentum $227M NASA, DLH $107M HHS), alongside near-term re-competes post-2024 endings. Watch outlay progress and option exercises amid maturing performance periods ending 2024-2028.

12 total filings